Billiontoone Inc Dossier - Source-backed chat

Billiontoone Inc

BLLNNASDAQ

SectorHealth Care

IndustryDiagnostics & Research

Beta (adjusted)1.00

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $105.76Price as of 1 Oct 2026

Data confidence Sign in to view data confidence

Market Cap $5B

Enterprise Value $4.5B

Shares Outstanding 47.2M diluted

Moat Rating Wide

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

BillionToOne, Inc. (NASDAQ: BLLN) is a rapidly growing, newly profitable molecular diagnostics company that is successfully disrupting the prenatal and oncology testing markets. Powered by its proprietary Quantitative Counting Templates (QCT) molecular counting platform, the company achieves single-molecule resolution that is up to 1,000 times more sensitive than standard next-generation sequencing. This technological edge allows BillionToOne to offer highly differentiated products, such as its UNITY prenatal screen (which assesses fetal risk for recessive conditions without requiring paternal DNA) and its Northstar liquid biopsy oncology tests. Having achieved GAAP profitability in late 2025 and demonstrating massive operating leverage with 84% YoY revenue growth in Q1 2026, BillionToOne represents a high-conviction growth play in precision medicine.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$90.00

Mean target$119.71

High · most bullish analyst$145.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$90.00

Increased competitive pressure from established players like Natera and Guardant Health slows down market share acquisition. Reimbursement headwinds or delays in payor contracting compress average selling prices (ASPs), causing gross margins to fall below 65% and pushing the company back into operating losses.

Base CaseCentral scenario

$119.71

Matches the consensus mean

BillionToOne executes in line with its raised FY2026 guidance, delivering total revenue of $450M to $465M (representing 48% to 52% YoY growth). The prenatal business maintains its steady market share gains, while oncology testing scales steadily. Gross margins stabilize around 70-73%, and the company maintains positive GAAP operating income throughout the year.

Bull CaseUpside scenario

$145.00

Oncology clinical testing revenue continues its hyper-growth trajectory (surging over 300% YoY) as Medicare coverage for Northstar Select expands and the company successfully launches its minimal residual disease (MRD) test in late 2026. Prenatal market share expands from 15% to over 25% in the US, driving total 2026 revenues above the high end of guidance ($465M) and expanding GAAP operating margins toward 20%.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Proprietary QCT platform technology provides a 1,000x sensitivity advantage over standard NGS, enabling unique single-gene NIPT and highly sensitive liquid biopsies.
Rapid financial inflection, with FY2025 revenue doubling to $305.1M and Q1 2026 demonstrating strong GAAP operating profitability (16% operating margin).
Strong commercial execution, delivering 188,000 tests in Q1 2026 (a 44% year-over-year increase) and having served over 500,000 patients historically.

Key Investment Risks

Intense competition in the molecular diagnostics space from well-capitalized incumbents such as Natera (NTRA) and Guardant Health (GH).
High dependence on payor contracts and reimbursement approvals, where any negative coverage decisions could severely impact average selling prices (ASPs).
Potential stock price volatility associated with post-IPO lock-up expirations and high short interest.

Thesis Invalidation Triggers

A drop in quarterly gross margins below 60% due to pricing pressure or rising cost-per-test.
A significant deceleration in oncology clinical testing revenue growth to below 50% YoY.
Loss of key Medicare or commercial payor coverage for the UNITY or Northstar product lines.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.